Exploring the role of mTOR pathway in aging and age-related disorders

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10500465" target="_blank" >RIV/00179906:_____/25:10500465 - isvavai.cz</a>

Alternative codes found

RIV/62690094:18470/25:50022554 RIV/62690094:18450/25:50022554

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ksjpIHz7jH" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ksjpIHz7jH</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.17179/excli2025-8384" target="_blank" >10.17179/excli2025-8384</a>

Result language

angličtina

Original language name

Exploring the role of mTOR pathway in aging and age-related disorders

Original language description

Aging is a highly intricate biochemical process. There is strong evidence suggesting that organismal aging, age-dependent diseases, and cellular senescence are related to the mammalian target of rapamycin (mTOR) signaling pathway. The signaling pathway of mTOR has become a prominent regulatory hub, managing crucial cellular activities that significantly affect lifespan and longevity. The mTOR is involved in controlling cell growth and metabolism in response to both internal and external energy signals as well as growth factors. The interaction between mTOR and cellular homeostasis is crucial in the aging process. This extensive review summarizes the most recent findings on mTOR inhibitors in the context of aging, highlighting their complex interactions with cellular systems, effect on longevity, and potential as therapeutic approaches for age-related diseases. Rapamycin and rapalogs (analogs of rapamycin), which have been proven to be effective mTOR inhibitors, have the ability to reduce the aging process in several model species while also enhancing metabolic health and stress responses. Despite cellular factors, mTOR inhibitors have revealed a potential path for therapeutics in age-related illnesses. These results suggest mTOR inhibitors as potential therapies to address the complex aspects of age-related diseases. However, obstacles stand in the way of clinical translation. Further research is required to improve dosing protocols, reduce potential side effects, and target mTOR inhibitors precisely at specific tissues. In summary, the mTOR signaling pathway is an important node in the intricate web of aging and its associated disorders.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

<a href="/en/project/GA23-05857S" target="_blank" >GA23-05857S: Alzheimer´s disease and aging: can mTOR inhibitors kill two birds with one drug?</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

EXCLI Journal

ISSN

1611-2156

e-ISSN

1611-2156

Volume of the periodical

24

Issue of the periodical within the volume

Aug

Country of publishing house

DE - GERMANY

Number of pages

24

Pages from-to

992-1015

UT code for WoS article

001544539200001

EID of the result in the Scopus database

2-s2.0-105013150226